References of "Struman, Ingrid"
     in
Bookmark and Share    
Peer Reviewed
See detailStudy of the role of miR-21 in the regulation of angiogenesis
Sabatel, Céline; Malvaux, Ludovic; Bovy, Nicolas ULg et al

Poster (2010, May)

Detailed reference viewed: 14 (1 ULg)
Peer Reviewed
See detailStudy of the role of miR-21 in the regulation of angiogenesis
Sabatel, Céline; Malvaux, Ludovic; Bovy, Nicolas ULg et al

Poster (2010, March)

Detailed reference viewed: 9 (1 ULg)
Peer Reviewed
See detailInvolvement of miR-125b in in vitro and in vivo angiogenesis
Malvaux, Ludovic; Pendeville, Hélène; Sabatel, Céline et al

Poster (2010, March)

Detailed reference viewed: 9 (0 ULg)
Peer Reviewed
See detail16K human prolactin is an anti-lymphangiogenic factor in vitro and in vivo
Kinet, Virginie; Castermans, Karolien; Blacher, Silvia ULg et al

Poster (2010, March)

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailEvaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study.
Sliwa, Karen; Blauwet, Lori; Tibazarwa, Kemi et al

in Circulation (2010), 121(13), 1465-73

BACKGROUND: Peripartum cardiomyopathy (PPCM) is a potentially life-threatening heart disease that occurs in previously healthy women. We identified prolactin, mainly its 16-kDa angiostatic and ... [more ▼]

BACKGROUND: Peripartum cardiomyopathy (PPCM) is a potentially life-threatening heart disease that occurs in previously healthy women. We identified prolactin, mainly its 16-kDa angiostatic and proapoptotic form, as a key factor in PPCM pathophysiology. Previous reports suggest that bromocriptine may have beneficial effects in women with acute onset of PPCM. METHODS AND RESULTS: A prospective, single-center, randomized, open-label, proof-of-concept pilot study of women with newly diagnosed PPCM receiving standard care (PPCM-Std; n=10) versus standard care plus bromocriptine for 8 weeks (PPCM-Br, n=10) was conducted. Because mothers receiving bromocriptine could not breast-feed, the 6-month outcome of their children (n=21) was studied as a secondary end point. Blinded clinical, hemodynamic, and echocardiographic assessments were performed at baseline and 6 months after diagnosis. Cardiac magnetic resonance imaging was performed 4 to 6 weeks after diagnosis in PPCM-Br patients. There were no significant differences in baseline characteristics, including serum 16-kDa prolactin levels and cathepsin D activity, between the 2 study groups. PPCM-Br patients displayed greater recovery of left ventricular ejection fraction (27% to 58%; P=0.012) compared with PPCM-Std patients (27% to 36%) at 6 months. One patient in the PPCM-Br group died compared with 4 patients in the PPCM-Std group. Significantly fewer PPCM-Br patients (n=1, 10%) experienced the composite end point of poor outcome defined as death, New York Heart Association functional class III/IV, or left ventricular ejection fraction <35% at 6 months compared with the PPCM-Std patients (n=8, 80%; P=0.006). Cardiac magnetic resonance imaging revealed no intracavitary thrombi. Infants of mothers in both groups showed normal growth and survival. CONCLUSIONS: In this trial, the addition of bromocriptine to standard heart failure therapy appeared to improve left ventricular ejection fraction and a composite clinical outcome in women with acute severe PPCM, although the number of patients studied was small and the results cannot be considered definitive. Larger-scale multicenter and blinded studies are in progress to test this strategy more robustly. [less ▲]

Detailed reference viewed: 17 (5 ULg)
Full Text
Peer Reviewed
See detailSprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis
Sabatel, Céline ULg; Cornet, Anne ULg; Tabruyn, Sébastien ULg et al

in Molecular Cancer (2010), 9(1), 231

BACKGROUND:Disorganized angiogenesis is associated with several pathologies, including cancer. The identification of new genes that control tumor neovascularization can provide novel insights for future ... [more ▼]

BACKGROUND:Disorganized angiogenesis is associated with several pathologies, including cancer. The identification of new genes that control tumor neovascularization can provide novel insights for future anti-cancer therapies. Sprouty1 (SPRY1), an inhibitor of the MAPK pathway, might be one of these new genes. We identified SPRY1 by comparing the transcriptomes of untreated endothelial cells with those of endothelial cells treated by the angiostatic agent 16K prolactin (16K hPRL). In the present study, we aimed to explore the potential function of SPRY1 in angiogenesis.RESULTS:We confirmed 16K hPRL induced up-regulation of SPRY1 in primary endothelial cells. In addition, we demonstrated the positive SPRY1 regulation in a chimeric mouse model of human colon carcinoma in which 16K hPRL treatment was shown to delay tumor growth. Expression profiling by qRT-PCR with species-specific primers revealed that induction of SPRY1 expression by 16K hPRL occurs only in the (murine) endothelial compartment and not in the (human) tumor compartment. The regulation of SPRY1 expression was NF-kappaB dependent. Partial SPRY1 knockdown by RNA interference protected endothelial cells from apoptosis as well as increased endothelial cell proliferation, migration, capillary network formation, and adhesion to extracellular matrix proteins. SPRY1 knockdown was also shown to affect the expression of cyclinD1 and p21 both involved in cell-cycle regulation. These findings are discussed in relation to the role of SPRY1 as an inhibitor of ERK/MAPK signaling and to a possible explanation of its effect on cell proliferation.CONCLUSIONS:Taken together, these results suggest that SPRY1 is an endogenous angiogenesis inhibitor. [less ▲]

Detailed reference viewed: 40 (15 ULg)
Peer Reviewed
See detailFinding miRNAs able to regulate angiogenesis
Pendeville, Helene; Nivelles, Olivier ULg; Malvaux, L. et al

Poster (2009, July)

Detailed reference viewed: 4 (0 ULg)
Peer Reviewed
See detailFinding Mir able to regulate angiogenesis
Pendeville, Helene; Nivelles, Olivier ULg; Malvaux, L. et al

Poster (2009, May 29)

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailStudy of the role of microRNAs in angiogenesis
Malvaux, Ludovic; Pendeville, Hélène; Sabatel, Céline et al

Poster (2009, May 29)

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailStudy of the potential regulation of Sprouty1, an angiogenesis inhibitor, by miR-21
Sabatel, Céline; Malvaux, Ludovic; Cornet, Anne et al

Poster (2009, May 29)

Detailed reference viewed: 8 (1 ULg)
Peer Reviewed
See detailEvaluation of the antitumor activity of 16K prolactin
Kinet, Virginie; Nguyen, Ngoc-Quynh-Nhu ULg; Sabatel, Céline et al

Poster (2009)

Detailed reference viewed: 24 (14 ULg)
Peer Reviewed
See detailRegulation of microRNAs expression by the antiangiogenic factor 16K hPRL
Halkein, Julie ULg; Malvaux, Ludovic; Nguyen, Ngoc-Quynh-Nhu ULg et al

Poster (2009)

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailNF-kappaB activation in endothelial cells is critical for the activity of angiostatic agents.
Tabruyn, Sébastien ULg; Memet, Sylvie; Ave, Patrick et al

in Molecular Cancer Therapeutics (2009), 8(9), 2645-54

In tumor cells, the transcription factor NF-kappaB has been described to be antiapoptotic and proproliferative and involved in the production of angiogenic factors such as vascular endothelial growth ... [more ▼]

In tumor cells, the transcription factor NF-kappaB has been described to be antiapoptotic and proproliferative and involved in the production of angiogenic factors such as vascular endothelial growth factor. From these data, a protumorigenic role of NF-kappaB has emerged. Here, we examined in endothelial cells whether NF-kappaB signaling pathway is involved in mediating the angiostatic properties of angiogenesis inhibitors. The current report describes that biochemically unrelated agents with direct angiostatic effect induced NF-kappaB activation in endothelial cells. Our data showed that endostatin, anginex, angiostatin, and the 16-kDa N-terminal fragment of human prolactin induced NF-kappaB activation in endothelial cells in both cultured human endothelial cells and in vivo in a mouse tumor model. It was also found that NF-kappaB activity was required for the angiostatic activity, because inhibition of NF-kappaB in endothelial cells impaired the ability of angiostatic agents to block sprouting of endothelial cells and to overcome endothelial cell anergy. Therefore, activation of NF-kappaB in endothelial cells can result in an unexpected antitumor outcome. Based on these data, the current approach of systemic treatment with NF-kappaB inhibitors may therefore be revisited because NF-kappaB activation specifically targeted to endothelial cells might represent an efficient strategy for the treatment of cancer. [less ▲]

Detailed reference viewed: 71 (13 ULg)
Full Text
Peer Reviewed
See detailAntiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth.
Kinet, Virginie ULg; Nguyen, Ngoc-Quynh-Nhu ULg; Sabatel, Céline ULg et al

in Cancer Letters (2009), 284(2), 222-228

Human 16K PRL (16K hPRL) is a potent inhibitor of angiogenesis both in vitro and in vivo. It has been shown to prevent tumor growth in three xenograft mouse models. Here we have used a gene transfer ... [more ▼]

Human 16K PRL (16K hPRL) is a potent inhibitor of angiogenesis both in vitro and in vivo. It has been shown to prevent tumor growth in three xenograft mouse models. Here we have used a gene transfer method based on cationic liposomes to produce 16K hPRL and demonstrate that 16K hPRL inhibits tumor growth in a subcutaneous B16F10 mouse melanoma model. Computer-assisted image analysis shows that 16K hPRL treatment results in the reduction of tumor vessel length and width, leading to a 57% reduction in average vessel size. We thus show, for the first time, that administration of the 16K hPRL gene complexed to cationic liposomes is effective to maintain antiangiogenic activities of 16K hPRL level. [less ▲]

Detailed reference viewed: 84 (34 ULg)
See detailNovel antiangiogenic peptide agents and their therapeutic and diagnostic use
Weiner, Richard I.; Martial, Joseph ULg; Struman, Ingrid ULg et al

Patent (2008)

The current invention concerns novel antiangiogenic peptides which correspond to about 10 to about 150 consecutive amino acids of N-terminal sequences of human growth hormones, human placental lactogen ... [more ▼]

The current invention concerns novel antiangiogenic peptides which correspond to about 10 to about 150 consecutive amino acids of N-terminal sequences of human growth hormones, human placental lactogen, human growth hormone variant hGH-V, and prolactin, and their use in inhibiting angiogenesis and in the diagnosis of diseases of human pregnancy involving abnormalities of placental vascularization. [less ▲]

Detailed reference viewed: 20 (5 ULg)